Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
Stock Information for Sorrento Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.